First Choice Medicare

Viral proteases are feasible targets for antiviral drugs. The main protease of SARS-CoV-2 plays a pivotal role in viral replication so inhibiting it could be an effective treatment for COVID-19. The antiviral drug nirmatrelvir, given with ritonavir, has been provisionally approved for the treatment of COVID-19 in adults who have an elevated risk of progressing to hospitalisation or death but do not require supplemental oxygen. This approval is based on incomplete data and may be revised with the publication of peer-reviewed results. The efficacy of the combination against the Omicron variant is not yet established. The combination is not approved for patients requiring hospitalisation for severe or critical COVID-19.

MOLNUPIRAVIR is given for emergency use to treat COVID-19. It is used by adults. One who is at high risk of covid19 complications.

Molnupiravir is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in non-hospitalized patients who are at high risk for progression to severe COVID-19 (eg, hospitalization, death) or in patients for whom other authorized or approved COVID-19 vaccines are not accessible or appropriate.